Meiyuan Jin

AUG 10, 2026 · JOURNAL ARTICLE

EngineeringNonpathogenic Bacteria for SynergisticTumor-Targeted Protein Degradation and Immunotherapy by Checkpoint-InhibitingNanobodies

Journal of the American Chemical Society

First-in-kind proof-of-concept study in animal models demonstrating a novel engineered bacterial platform; lacks human efficacy data, comparator arm, and dose-ranging or safety characterization needed to establish clinical relevance.